CA2219678C - Use of allylamine derivatives such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection or associated diseases - Google Patents
Use of allylamine derivatives such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection or associated diseases Download PDFInfo
- Publication number
- CA2219678C CA2219678C CA002219678A CA2219678A CA2219678C CA 2219678 C CA2219678 C CA 2219678C CA 002219678 A CA002219678 A CA 002219678A CA 2219678 A CA2219678 A CA 2219678A CA 2219678 C CA2219678 C CA 2219678C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- formula
- pylori infection
- pharmaceutically acceptable
- associated diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Use of compounds of formula I
Description
USE OF ALLYLAMINE DERIVATIVES SUCH AS TERBINAFINE, IN THE
MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HELICOBACTER
PYLORI INFECTION OR ASSOCIATED DISEASES
The invention relates to a new therapeutic use of certain allylamine compounds.
Allylamines are known for being squalene epoxidase inhibitors and exhibit antimycotic activity. Surprisingly it was now found that some compounds of this class are also active against Helicobacter pylori (Campylobacter pyloridis).
Members of the genus Helicobacter are gram-negative spiral bacteria that are usually found in the mucus layer of the stomach of humans and animals. They are microaerophilic, possess flagella, and produce numerous extracellular products, including urease, proteases, and other compounds that enable them to survive in the hostile environment of the stomach. Worldwide, approximately half of the human population are H.pylori-positive. Without eradication therapy, established Helicobacter pylori infection seems to persist for life. H.pylori infection regularly results in chronic active gastritis (type-B gastritis), but rarely becomes clinically evident. Recently, a causal relationship between H.pylori infection and peptic ulcer disease has been proven.
Furthermore, on the basis of previous epidemiological evidence, H.pylori has been classified as a category 1 (definite) human carcinogen by the WHO (World Health Organization). The difficulties faced in assessing the risk of gastric cancer in different susceptible populations have been addressed and new data presented to support a model of chronic gastritis leading to atrophy, followed by intestinal metaplasia and gastric cancer.
It has now been found that some compounds of the allylamine class of antimycotics exhibit excellent inhibitory activity against H.pylori. They are therefore useful in the therapy in the above mentioned diseases.
MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HELICOBACTER
PYLORI INFECTION OR ASSOCIATED DISEASES
The invention relates to a new therapeutic use of certain allylamine compounds.
Allylamines are known for being squalene epoxidase inhibitors and exhibit antimycotic activity. Surprisingly it was now found that some compounds of this class are also active against Helicobacter pylori (Campylobacter pyloridis).
Members of the genus Helicobacter are gram-negative spiral bacteria that are usually found in the mucus layer of the stomach of humans and animals. They are microaerophilic, possess flagella, and produce numerous extracellular products, including urease, proteases, and other compounds that enable them to survive in the hostile environment of the stomach. Worldwide, approximately half of the human population are H.pylori-positive. Without eradication therapy, established Helicobacter pylori infection seems to persist for life. H.pylori infection regularly results in chronic active gastritis (type-B gastritis), but rarely becomes clinically evident. Recently, a causal relationship between H.pylori infection and peptic ulcer disease has been proven.
Furthermore, on the basis of previous epidemiological evidence, H.pylori has been classified as a category 1 (definite) human carcinogen by the WHO (World Health Organization). The difficulties faced in assessing the risk of gastric cancer in different susceptible populations have been addressed and new data presented to support a model of chronic gastritis leading to atrophy, followed by intestinal metaplasia and gastric cancer.
It has now been found that some compounds of the allylamine class of antimycotics exhibit excellent inhibitory activity against H.pylori. They are therefore useful in the therapy in the above mentioned diseases.
The invention concerns the use of a compound of formula I
R
\ /
Wherein either R is attached at the 1 or 2 position of the naphthyl ring and is -CH2IV(CH3~H2CH~CHC~C-C(CH3~;
or R is attached at the 1 position and is -CH2N(CH3~CH2CIi~CH- phenyl or N-[(E)-3-phenyl-2-propenyl]-2-piperidinyl, in free base form or in pharmaceutically acceptable salt form, in the therapy of Helicobacter pylori infection and associated diseases such as gastritis, peptic ulcer, duodenal ulcer, gastric atrophy, intestinal metaplasia, non-ulcerative dyspepsia, MALT lymphoma (lymphoma of gastric mucosa - associated lymphatic tissue), non-Hodgkin's lymphoma and gastric cancer whereby the subject suffering from H. pylori infection is not suffering from or is not being treated for, mycotic infection, hereinafter briefly named "the use of the invention".
It also concerns the use of a compound of formula I as defined above in free base form or in pharmaceutically acceptable salt form for the manufacture of a medicament for use in the therapy of Helicobacter pylori infection and associated diseases as defined above, optionally in combination with one or more other, preferably orally active agents.
It further concerns a method of treatment of Helicobacter pylori infection and associated diseases as defined above, comprising administration of a therapeutically effective amount of a compound of formula I as defined above in free base form or in pharmaceutically acceptable salt form to a subject in need of such treatment.
Administration may optionally be effected in combination with one or more other, preferably orally active agent.
It further concerns an agent for use in the therapy of Helicobacter pylori infection and associated diseases as defined above, comprising a compound of formula I
in free base form or in pharmaceutically acceptable salt form together with at least one pharmaceutically acceptable carrier or diluent, optionally in combination with one or more other, preferably orally active agents.
R
\ /
Wherein either R is attached at the 1 or 2 position of the naphthyl ring and is -CH2IV(CH3~H2CH~CHC~C-C(CH3~;
or R is attached at the 1 position and is -CH2N(CH3~CH2CIi~CH- phenyl or N-[(E)-3-phenyl-2-propenyl]-2-piperidinyl, in free base form or in pharmaceutically acceptable salt form, in the therapy of Helicobacter pylori infection and associated diseases such as gastritis, peptic ulcer, duodenal ulcer, gastric atrophy, intestinal metaplasia, non-ulcerative dyspepsia, MALT lymphoma (lymphoma of gastric mucosa - associated lymphatic tissue), non-Hodgkin's lymphoma and gastric cancer whereby the subject suffering from H. pylori infection is not suffering from or is not being treated for, mycotic infection, hereinafter briefly named "the use of the invention".
It also concerns the use of a compound of formula I as defined above in free base form or in pharmaceutically acceptable salt form for the manufacture of a medicament for use in the therapy of Helicobacter pylori infection and associated diseases as defined above, optionally in combination with one or more other, preferably orally active agents.
It further concerns a method of treatment of Helicobacter pylori infection and associated diseases as defined above, comprising administration of a therapeutically effective amount of a compound of formula I as defined above in free base form or in pharmaceutically acceptable salt form to a subject in need of such treatment.
Administration may optionally be effected in combination with one or more other, preferably orally active agent.
It further concerns an agent for use in the therapy of Helicobacter pylori infection and associated diseases as defined above, comprising a compound of formula I
in free base form or in pharmaceutically acceptable salt form together with at least one pharmaceutically acceptable carrier or diluent, optionally in combination with one or more other, preferably orally active agents.
The invention further concerns a process for the preparation of a medicament for use as defined above, which comprises mixing a compound of formula I in free base form or in pharmaceutically acceptable salt form optionally in combination with one or more other, preferably orally active agents together with at least one pharmaceutically acceptable carrier or diluent.
It also concerns a pharmaceutical composition adapted for use as defined above, which comprises a compound of formula I in free base form or in pharmaceutically acceptable salt form optionally in combination with one or more other active agents and is compounded as an orally administrable capsule shell or drink solution for release and activity in the gastrointestinal system.
The compounds of formula I in free base or salt form, methods for their preparation and their use as antimycotics, are known from e.g. EP 24587, USP
It also concerns a pharmaceutical composition adapted for use as defined above, which comprises a compound of formula I in free base form or in pharmaceutically acceptable salt form optionally in combination with one or more other active agents and is compounded as an orally administrable capsule shell or drink solution for release and activity in the gastrointestinal system.
The compounds of formula I in free base or salt form, methods for their preparation and their use as antimycotics, are known from e.g. EP 24587, USP
4'282'251, EP 00896, GB 2'051'799 and/or A. Stiitz, Ann. N.Y. Acad. Sci. 544 (1988) 46-62.
A compound of formula I may exist in free base form or in salt, particularly acid addition salt form. It preferably is in salt form, e.g. the hydrochloride salt form. When R
includes the 2-piperidinyl moiety it may also be in optically active form, e.g. as the (R)(-~-)enantiomer.
R preferably is attached at the 1 position. R preferably includes a triple bond. R
especially is attached at the 1 position and includes a triple bond; when that compound is in hydrochloride salt form it is known as terbinafine (Lamisil~ ) .
A subgroup of compounds of formula I is the compounds of formula I as defined above, with the exception of terbinafine.
The term "therapy" should be understood to apply for prophylactic as well as curative treatment. The subject suffering from H.pylori infection preferably is not suffering from, or is not being treated for, mycotic infection; in a subgroup the subject suffering from H.pylori infection preferably is not suffering from, or is not being treated for, mycotic, ringworm or yeast infection.
The activity of the compounds of formula I against Helicobacter pylori can be verified e.g. by determination of the MIC (minimum inhibitory concentration) in the following test method using various clinical isolates of H.pylori:
Clinical isolates of H.pylori are stored at -70°C in Brucella broth with 20%
glycerol. All isolates are subcultured on fresh blood agar (Blood agar base No. 2, Unipath, with 5% defibrinated horse blood) and confirmed as Helicobacter pylori by Gram stain, catalase, oxidase and rapid-urease tests. Initial incubation is carried out microaerobically in a variable-atmosphere incubator (6% OZ, 10% COZ, 3% H2, 81 % NZ) , at 37°C. Subcultures and MIC tests are carried out in humidified air with 5% COZ at 37°C. Test compounds are incorporated into Mueller-Hinton agar (LTnipath) with 7%
defibrinated horse blood at pH 7.2. After growth for 72 hours on blood agar H.pylori suspensions are made in Brucella broth (Unipath) equivalent to McFarland standard No. 3. This represents 108 cfu/ml H.pylori. A multipoint inoculator will deliver 1 p1 per spot (approximately 105 cfu). The type strain NCTC 11637 is used as a control in each run. Plates are incubated for 72 hours and the MIC is taken as the lowest concentration of test compound to completely inhibit growth. All tests are carried out in triplicate.
In the above test the compounds of formula I have a MIC of from about 0.06 mg/1 to about 30 mg/1. Thus, the compound of formula I in R(+)-enantiomeric and hydrochloride salt form and wherein R is N-[(E)-3-phenyl-2-propenyl-2-piperidinyl attached at the I position is found to have MIC values of 0.06-4 mg/1, the remaining three compounds of formula I in hydrochloride salt form, MIC values of 8-32 mg/1.
The compounds of formula I in free base form or in pharmaceutically acceptable salt form are therefore useful as agents in the therapy of Helicobacter pylori infection and associated diseases such as gastritis, peptic ulcer, duodenal ulcer, atrophy, intestinal metaplasia, non-ulcerative dyspepsia, MALT lymphoma, non-Hodgkin's lymphoma and gastric cancer. For this use, the effective dosage will, of course, vary depending on the particular agent employed, the mode of administration and the treatment desired.
However, in general, satisfactory results are obtained when the agents are administered at a daily dosage of from about 0.02 mg/kg to about 50 mg/kg animal body weight, suitably given in divided doses two to four times daily. For most large mammals the total daily dosage is from about 1 mg to about 3500 mg, preferably from about 10 mg to about 2000 mg, especially from about 500 mg to about 1500 mg, especially from about 550 mg to about 1200 mg, especially about 600 mg, given once or twice daily. They may be administered in similar manner to known standards for use in such indications.
It is indicated that for this use they may be administered to larger mammals, for example humans, by similar modes of administration at similar or lower dosages than conventionally employed with known standards for such indications.
The usefulness of the compounds of formula I in free base or in pharmaceutically acceptable salt form in the above indications is also indicated in standard clinical trials.
A representative clinical trial may be effected as follows:
The trial is conducted employing a group of volunteers (mixed male and female of average body weight) identified as exhibiting H.pylori infection as assessed by e.g. an appropriate breath test (urease test) or antibody test, and are then given an endoscopic examination. Subjects selected are primarily selected from long-term sufferers and non-responders to conventional therapy. Each subject receives a composition in accordance with the invention, e.g. a tablet. Compositions are applied orally in an amount of from about 10 mg to about 1000 mg. Administration is effected 1, 2 or 3 times daily. Treatment is continued for each subject for a period between 7 days and weeks, preferably about 2 to 4 weeks. After a further period without treatment of between 7 days and 6 weeks, preferably about 4 weeks, a second assessment by e.g.
breath test is given to determine the H.pylori status of the subject, and a second endoscopic examination is effected. Alternative treatment is withdrawn prior to and during treatment with the compound to be tested. Each subject undergoes full gastric examination prior to commencement of treatment to determine extent, location and severity of lesions. Each subject is also questioned to determine subjective experience of the disease. Examination is repeated at the conclusion of treatment and all changes in condition are noted. At the conclusion of treatment each subject is again questioned to determine subjective experience of the disease. All changes in the subjects' condition, especially extent, intensity of lesion as well as any side effects, are noted, with particular emphasis on the determination of eradication of H.pylori. Results obtained on administration of composition in accordance with the invention are compared with those obtained for a control group receiving a placebo composition not comprising the compound to be tested. Results obtained show marked reduction of gastritis in subjects receiving compositions in accordance with the invention administered as described as compared with control groups receiving placebo. Compositions in accordance with the invention tested are found to be well tolerated.
The agents are well tolerated. The acute toxicity in the mouse of representative compounds of formula I is as follows:
- compound of formula I in hydrochloride salt form and wherein R is attached at the 1 position and is -CHZN(CH3)CHZCH~-NCH-phenyl: LDso p.o. > 1000 mg/kg;
LDso i.p.: ~ 560 mg/kg;
- compound of formula I in hydrochloride salt form and wherein R is attached at the 1 position and is -CH2N(CH3)CH2CH~CHC--C-C(CH3)3: LDP p.o_ > 1000 mg/kg;
LDso i.p. = 790 mg/kg.
The tolerability of other compounds falling under the scope may be determined in conventional manner, and is indicated to be of the same order as that of the representative examples above.
The agents are optionally administered in combination with one or more other, preferably orally active agents such as an HZ receptor blocker, e.g.
cimetidine, ranitidine or famotidine, an azole such as omeprazol or metronidazol, or a basic aluminium complex such as sucralfate. The dosages of the components of such combinations are similar or lower than conventionally employed.
The compounds of formula I in free base form or in pharmaceutically acceptable salt form, optionally in combination with one or more other, preferably orally active agents may be admixed with conventional chemotherapeutically acceptable diluents and carriers and administered e.g. parenterally or intravenously, preferably orally, in such forms as tablets or capsules. The concentrations of active substance will, of course, vary depending e.g. on the compound employed, the treatment desired and the nature of the form.
The pharmaceutical compositions for oral use are preferably compounded in unit dosage form, for example by filling them into orally administrable capsule shells. The capsule shells may be soft or hard gelatine capsule shells. However, if desired the pharmaceutical compositions may be in a drink solution form and may include water or any other aqueous system, to provide emulsion or microemulsion systems suitable for drinking.
A compound of formula I may exist in free base form or in salt, particularly acid addition salt form. It preferably is in salt form, e.g. the hydrochloride salt form. When R
includes the 2-piperidinyl moiety it may also be in optically active form, e.g. as the (R)(-~-)enantiomer.
R preferably is attached at the 1 position. R preferably includes a triple bond. R
especially is attached at the 1 position and includes a triple bond; when that compound is in hydrochloride salt form it is known as terbinafine (Lamisil~ ) .
A subgroup of compounds of formula I is the compounds of formula I as defined above, with the exception of terbinafine.
The term "therapy" should be understood to apply for prophylactic as well as curative treatment. The subject suffering from H.pylori infection preferably is not suffering from, or is not being treated for, mycotic infection; in a subgroup the subject suffering from H.pylori infection preferably is not suffering from, or is not being treated for, mycotic, ringworm or yeast infection.
The activity of the compounds of formula I against Helicobacter pylori can be verified e.g. by determination of the MIC (minimum inhibitory concentration) in the following test method using various clinical isolates of H.pylori:
Clinical isolates of H.pylori are stored at -70°C in Brucella broth with 20%
glycerol. All isolates are subcultured on fresh blood agar (Blood agar base No. 2, Unipath, with 5% defibrinated horse blood) and confirmed as Helicobacter pylori by Gram stain, catalase, oxidase and rapid-urease tests. Initial incubation is carried out microaerobically in a variable-atmosphere incubator (6% OZ, 10% COZ, 3% H2, 81 % NZ) , at 37°C. Subcultures and MIC tests are carried out in humidified air with 5% COZ at 37°C. Test compounds are incorporated into Mueller-Hinton agar (LTnipath) with 7%
defibrinated horse blood at pH 7.2. After growth for 72 hours on blood agar H.pylori suspensions are made in Brucella broth (Unipath) equivalent to McFarland standard No. 3. This represents 108 cfu/ml H.pylori. A multipoint inoculator will deliver 1 p1 per spot (approximately 105 cfu). The type strain NCTC 11637 is used as a control in each run. Plates are incubated for 72 hours and the MIC is taken as the lowest concentration of test compound to completely inhibit growth. All tests are carried out in triplicate.
In the above test the compounds of formula I have a MIC of from about 0.06 mg/1 to about 30 mg/1. Thus, the compound of formula I in R(+)-enantiomeric and hydrochloride salt form and wherein R is N-[(E)-3-phenyl-2-propenyl-2-piperidinyl attached at the I position is found to have MIC values of 0.06-4 mg/1, the remaining three compounds of formula I in hydrochloride salt form, MIC values of 8-32 mg/1.
The compounds of formula I in free base form or in pharmaceutically acceptable salt form are therefore useful as agents in the therapy of Helicobacter pylori infection and associated diseases such as gastritis, peptic ulcer, duodenal ulcer, atrophy, intestinal metaplasia, non-ulcerative dyspepsia, MALT lymphoma, non-Hodgkin's lymphoma and gastric cancer. For this use, the effective dosage will, of course, vary depending on the particular agent employed, the mode of administration and the treatment desired.
However, in general, satisfactory results are obtained when the agents are administered at a daily dosage of from about 0.02 mg/kg to about 50 mg/kg animal body weight, suitably given in divided doses two to four times daily. For most large mammals the total daily dosage is from about 1 mg to about 3500 mg, preferably from about 10 mg to about 2000 mg, especially from about 500 mg to about 1500 mg, especially from about 550 mg to about 1200 mg, especially about 600 mg, given once or twice daily. They may be administered in similar manner to known standards for use in such indications.
It is indicated that for this use they may be administered to larger mammals, for example humans, by similar modes of administration at similar or lower dosages than conventionally employed with known standards for such indications.
The usefulness of the compounds of formula I in free base or in pharmaceutically acceptable salt form in the above indications is also indicated in standard clinical trials.
A representative clinical trial may be effected as follows:
The trial is conducted employing a group of volunteers (mixed male and female of average body weight) identified as exhibiting H.pylori infection as assessed by e.g. an appropriate breath test (urease test) or antibody test, and are then given an endoscopic examination. Subjects selected are primarily selected from long-term sufferers and non-responders to conventional therapy. Each subject receives a composition in accordance with the invention, e.g. a tablet. Compositions are applied orally in an amount of from about 10 mg to about 1000 mg. Administration is effected 1, 2 or 3 times daily. Treatment is continued for each subject for a period between 7 days and weeks, preferably about 2 to 4 weeks. After a further period without treatment of between 7 days and 6 weeks, preferably about 4 weeks, a second assessment by e.g.
breath test is given to determine the H.pylori status of the subject, and a second endoscopic examination is effected. Alternative treatment is withdrawn prior to and during treatment with the compound to be tested. Each subject undergoes full gastric examination prior to commencement of treatment to determine extent, location and severity of lesions. Each subject is also questioned to determine subjective experience of the disease. Examination is repeated at the conclusion of treatment and all changes in condition are noted. At the conclusion of treatment each subject is again questioned to determine subjective experience of the disease. All changes in the subjects' condition, especially extent, intensity of lesion as well as any side effects, are noted, with particular emphasis on the determination of eradication of H.pylori. Results obtained on administration of composition in accordance with the invention are compared with those obtained for a control group receiving a placebo composition not comprising the compound to be tested. Results obtained show marked reduction of gastritis in subjects receiving compositions in accordance with the invention administered as described as compared with control groups receiving placebo. Compositions in accordance with the invention tested are found to be well tolerated.
The agents are well tolerated. The acute toxicity in the mouse of representative compounds of formula I is as follows:
- compound of formula I in hydrochloride salt form and wherein R is attached at the 1 position and is -CHZN(CH3)CHZCH~-NCH-phenyl: LDso p.o. > 1000 mg/kg;
LDso i.p.: ~ 560 mg/kg;
- compound of formula I in hydrochloride salt form and wherein R is attached at the 1 position and is -CH2N(CH3)CH2CH~CHC--C-C(CH3)3: LDP p.o_ > 1000 mg/kg;
LDso i.p. = 790 mg/kg.
The tolerability of other compounds falling under the scope may be determined in conventional manner, and is indicated to be of the same order as that of the representative examples above.
The agents are optionally administered in combination with one or more other, preferably orally active agents such as an HZ receptor blocker, e.g.
cimetidine, ranitidine or famotidine, an azole such as omeprazol or metronidazol, or a basic aluminium complex such as sucralfate. The dosages of the components of such combinations are similar or lower than conventionally employed.
The compounds of formula I in free base form or in pharmaceutically acceptable salt form, optionally in combination with one or more other, preferably orally active agents may be admixed with conventional chemotherapeutically acceptable diluents and carriers and administered e.g. parenterally or intravenously, preferably orally, in such forms as tablets or capsules. The concentrations of active substance will, of course, vary depending e.g. on the compound employed, the treatment desired and the nature of the form.
The pharmaceutical compositions for oral use are preferably compounded in unit dosage form, for example by filling them into orally administrable capsule shells. The capsule shells may be soft or hard gelatine capsule shells. However, if desired the pharmaceutical compositions may be in a drink solution form and may include water or any other aqueous system, to provide emulsion or microemulsion systems suitable for drinking.
Claims (9)
1. Use of a compound of formula I
wherein either R is attached at the 1 or 2 position of the naphthyl ring and is -CH2N(CH3)CH2CH~CHC.ident.C(CH3)3;
or R is attached at the 1 position and is -CH2N(CH3)CH2CH~CH-phenyl or N-[(E)-3phenyl-2-propenyl]-2-piperidinyl, in free base form or in pharmaceutically acceptable salt form, for the manufacture of a medicament for use in the therapy of Helicobacter pylori infection and associated diseases whereby the subject suffering from H. pylori infection is not suffering from, or is not being treated for, mycotic infection.
wherein either R is attached at the 1 or 2 position of the naphthyl ring and is -CH2N(CH3)CH2CH~CHC.ident.C(CH3)3;
or R is attached at the 1 position and is -CH2N(CH3)CH2CH~CH-phenyl or N-[(E)-3phenyl-2-propenyl]-2-piperidinyl, in free base form or in pharmaceutically acceptable salt form, for the manufacture of a medicament for use in the therapy of Helicobacter pylori infection and associated diseases whereby the subject suffering from H. pylori infection is not suffering from, or is not being treated for, mycotic infection.
2. Use according to claim 1 wherein the associated diseases are selected from gastritis, peptic ulcer, duodenal ulcer, gastric atrophy, intestinal metaplasia, non-ulcerative dyspepsia, MALT lymphoma, non-Hodgkin's lymphoma and gastric cancer.
3. Use according to claim 1 or 2 of the compound of formula I as defined in claim 1 wherein R is attached at the 1 position and is -CH2N(CH3)CH2CH~CHC.ident.C-C(CH3)3 , in free base form or in pharmaceutically acceptable salt form.
4. Use according to claim 3 wherein the compound is in the form of the hydrochloride salt.
5. A composition for use in the therapy of Helicobacter pylori infection and associated diseases as defined in claim 1 or 2, whereby the subject suffering from H.
pylori infection is not suffering from, or is not being treated for, mycotic infection, comprising a compound of formula I as defined in claim 1 in free base form or in pharmaceutically acceptable salt form together with at least one pharmaceutically acceptable carrier or diluent.
pylori infection is not suffering from, or is not being treated for, mycotic infection, comprising a compound of formula I as defined in claim 1 in free base form or in pharmaceutically acceptable salt form together with at least one pharmaceutically acceptable carrier or diluent.
6. A pharmaceutical composition for use in the therapy of Helicobacter pylori infection and associated diseases as defined in claim for 2, whereby the subject suffering from H. pylori infection is not suffering from, on is not being treated for, mycotic infection, which comprises a compound of formula I as defined in claim 1 in free base form or in pharmaceutically acceptable salt form, optionally in combination with one or more other active agents, compounded as an orally administrable capsule shell or drink solution for release and activity in the gastrointestinal system.
7. Use according to claim 1 wherein the compound of formula I as defined in claim 1 is in combination with one or more other, orally active agents selected from the group consisting of cimetidine, ranitidine, famotidine, omeprazol, metronidazol and sucralfate.
8. A composition according to claim 5 wherein the compound of formula I as defined in claim 1 is in combination with one or more other, orally active agents selected from the group consisting of cimetidine, ranitidine, famotidine, omeprazol, metronidazol and sucralfate.
9. A pharmaceutical composition according to claim 6 wherein the compound of formula I as defined in claim 1 is in combination with one or more other, orally active agents selected from the group consisting of cimetidine, ranitidine, famotidine, omeprazol, metronidazol and sucralfate.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9513750.1 | 1995-07-06 | ||
| GBGB9513750.1A GB9513750D0 (en) | 1995-07-06 | 1995-07-06 | Use of allylamines |
| PCT/EP1996/002970 WO1997002026A1 (en) | 1995-07-06 | 1996-07-05 | Use of allylamine derivatives such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection of associated diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2219678A1 CA2219678A1 (en) | 1997-01-23 |
| CA2219678C true CA2219678C (en) | 2006-10-10 |
Family
ID=10777201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002219678A Expired - Fee Related CA2219678C (en) | 1995-07-06 | 1996-07-05 | Use of allylamine derivatives such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection or associated diseases |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US5935998A (en) |
| EP (1) | EP0863752B1 (en) |
| JP (1) | JP3680950B2 (en) |
| KR (1) | KR100425401B1 (en) |
| CN (1) | CN1204881C (en) |
| AT (1) | ATE232723T1 (en) |
| AU (1) | AU715270B2 (en) |
| CA (1) | CA2219678C (en) |
| CY (1) | CY2465B1 (en) |
| CZ (1) | CZ289440B6 (en) |
| DE (1) | DE69626301T2 (en) |
| DK (1) | DK0863752T3 (en) |
| ES (1) | ES2192608T3 (en) |
| GB (1) | GB9513750D0 (en) |
| HK (1) | HK1011527A1 (en) |
| HU (1) | HU224311B1 (en) |
| IL (1) | IL122853A (en) |
| MX (1) | MX9710093A (en) |
| MY (1) | MY132436A (en) |
| NO (1) | NO317496B1 (en) |
| PL (1) | PL187704B1 (en) |
| RU (1) | RU2193402C2 (en) |
| SI (1) | SI0863752T1 (en) |
| SK (1) | SK282874B6 (en) |
| TW (1) | TW522011B (en) |
| WO (1) | WO1997002026A1 (en) |
| ZA (1) | ZA965749B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0001315D0 (en) * | 2000-01-20 | 2000-03-08 | Novartis Ag | Organic compounds |
| US7244703B2 (en) * | 2001-06-22 | 2007-07-17 | Bentley Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for peptide treatment |
| KR20030066186A (en) * | 2002-02-05 | 2003-08-09 | 한솔케미언스 주식회사 | Process for preparation of Terbinafin |
| EA010885B1 (en) | 2003-12-08 | 2008-12-30 | Бентли Фармасьютикалз, Инк. | Pharmaceutical compositions and methods for insulin treatment |
| RU2449805C1 (en) | 2011-01-27 | 2012-05-10 | Общество С Ограниченной Ответственностью "Гармония" | Peptide pharmaceutical composition, based drug for gastroduodenal diseases caused by helicobacter pylori, and method of using it |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2716943C2 (en) * | 1976-04-28 | 1986-08-14 | Sandoz-Patent-GmbH, 7850 Lörrach | N- (3-Phenyl-2-propenyl) -N- (1-naphthylmethyl) amines, their use and preparation |
| EP0000896B1 (en) * | 1977-08-19 | 1982-10-13 | Sandoz Ag | Propenyl amines, processes for their production and pharmaceutical compositions containing them |
| DE3020113A1 (en) * | 1979-06-08 | 1980-12-18 | Sandoz Ag | 2- (1-NAPHTHYL) PIPERIDINE DERIVATIVE, THE PRODUCTION THEREOF AND THE USE AS AN ANTIMYCOTIC |
| CY1410A (en) * | 1979-08-22 | 1988-04-22 | Sandoz Ag | Propenylamines, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals |
| US5132459A (en) * | 1979-08-22 | 1992-07-21 | Sandoz Ltd. | Propenylamines, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals |
| US4894375A (en) * | 1986-09-29 | 1990-01-16 | Merck & Co., Inc. | Method of controlling mycotic infections and compositions therefor |
| CA2020888A1 (en) * | 1989-07-27 | 1991-01-28 | Philippe Guerry | Substituted aminoalkoxybenzene derivatives |
| US5200195A (en) * | 1991-12-06 | 1993-04-06 | Alza Corporation | Process for improving dosage form delivery kinetics |
| DE4317449A1 (en) * | 1993-05-19 | 1994-11-24 | Asche Ag | Pharmaceutical composition for the treatment of disorders of the gastrointestinal tract |
-
1995
- 1995-07-06 GB GBGB9513750.1A patent/GB9513750D0/en active Pending
-
1996
- 1996-07-05 JP JP50483397A patent/JP3680950B2/en not_active Expired - Fee Related
- 1996-07-05 CZ CZ199817A patent/CZ289440B6/en not_active IP Right Cessation
- 1996-07-05 AU AU65195/96A patent/AU715270B2/en not_active Ceased
- 1996-07-05 ES ES96924889T patent/ES2192608T3/en not_active Expired - Lifetime
- 1996-07-05 HU HU9802929A patent/HU224311B1/en not_active IP Right Cessation
- 1996-07-05 WO PCT/EP1996/002970 patent/WO1997002026A1/en active IP Right Grant
- 1996-07-05 RU RU98102187/14A patent/RU2193402C2/en not_active IP Right Cessation
- 1996-07-05 AT AT96924889T patent/ATE232723T1/en not_active IP Right Cessation
- 1996-07-05 MX MX9710093A patent/MX9710093A/en not_active IP Right Cessation
- 1996-07-05 CN CNB96195289XA patent/CN1204881C/en not_active Expired - Fee Related
- 1996-07-05 DE DE69626301T patent/DE69626301T2/en not_active Expired - Lifetime
- 1996-07-05 SI SI9630594T patent/SI0863752T1/en unknown
- 1996-07-05 US US08/981,324 patent/US5935998A/en not_active Expired - Fee Related
- 1996-07-05 SK SK6-98A patent/SK282874B6/en not_active IP Right Cessation
- 1996-07-05 ZA ZA9605749A patent/ZA965749B/en unknown
- 1996-07-05 PL PL96323305A patent/PL187704B1/en not_active IP Right Cessation
- 1996-07-05 DK DK96924889T patent/DK0863752T3/en active
- 1996-07-05 CA CA002219678A patent/CA2219678C/en not_active Expired - Fee Related
- 1996-07-05 MY MYPI96002783A patent/MY132436A/en unknown
- 1996-07-05 EP EP96924889A patent/EP0863752B1/en not_active Expired - Lifetime
- 1996-07-05 KR KR10-1998-0700023A patent/KR100425401B1/en not_active IP Right Cessation
- 1996-07-05 IL IL12285396A patent/IL122853A/en not_active IP Right Cessation
- 1996-07-06 TW TW085108161A patent/TW522011B/en not_active IP Right Cessation
-
1997
- 1997-12-09 NO NO19975790A patent/NO317496B1/en not_active IP Right Cessation
-
1998
- 1998-12-07 HK HK98112906A patent/HK1011527A1/en not_active IP Right Cessation
-
2004
- 2004-07-02 CY CY0400055A patent/CY2465B1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0226266B1 (en) | Use of a tetrahydrocarbazolone derivative for the manufacture of medicaments | |
| HU229292B1 (en) | New pharmaceutical composition | |
| IE861395L (en) | Alfuzosine compositions | |
| US7713984B2 (en) | Pharmaceutical uses | |
| CA2219678C (en) | Use of allylamine derivatives such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection or associated diseases | |
| FR2904774A1 (en) | SOLID PHARMACEUTICAL COMPOSITION CONTAINING A COMBINATION OF A REGULATOR AGENT FOR INTESTINAL MOTILITY AND AN ANTIFLATULENT. | |
| CN1859948B (en) | Carbostyril derivatives for accelerating salivation | |
| JPH0930970A (en) | Antimicrobial agent | |
| US6300343B1 (en) | Method of treatment | |
| JP2021535910A (en) | Composition for eradicating Helicobacter pylori | |
| CA1174169A (en) | Orally active tolciclate and tolnaftate | |
| FR2605884A1 (en) | NEW DRUG ASSOCIATION | |
| JP3490146B2 (en) | Anti-Helicobacter pylori agent | |
| JPH11189529A (en) | Anti-helicobacter pylori agent | |
| JP2002265354A (en) | Anti-helicobacter pylori agent composition | |
| KR20010052895A (en) | Method of Treatment | |
| JP2612417B2 (en) | Gastrointestinal symptom improver | |
| AU690664B2 (en) | Low dosage ranitidine compositions for the treatment of minor gastrointestinal disorders associated with excess acid secretion | |
| JP2898930B2 (en) | Gastrointestinal symptom improver | |
| Franco-Paredes | Mycobacterium leprae | |
| FR2566664A1 (en) | Compsn. for treatment of diarrhoea | |
| MXPA05009025A (en) | Therapeutic agent for diarrhea-type irritable bowel syndrome. | |
| JPH01197443A (en) | Non-steroidal anti-inflammatory composition containing h1 blocker, h2 blocker, beta-adrenarine action agent or combination thereof and alkali agent and production thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |